Specialist Hospital Treats 288 Patients with Genetically Engineered T-Cells

King Faisal Specialist Hospital and Research Centre successfully treated 288 patients using genetically engineered T-cells (CAR-T) as of the end of October 2026, for certain types of blood cancer, a figure reflecting the growth of its clinical expertise in delivering advanced immunotherapies.
The cases included 251 adults and 37 children, who accounted for about 13% of the total patients who received the treatment, which relies on extracting immune cells from the patient's blood and genetically engineering them to recognize and attack cancer cells, before reinfusing them into the body.
The program has seen growth in its therapeutic and manufacturing capabilities, with the hospital shifting from manufacturing the treatment abroad to producing it locally, as two patients received the treatment manufactured inside the hospital, following the first dose administered in a Phase I clinical trial in 2025.
Local manufacturing helped cut the treatment's production and delivery time from 28 days to less than 14 days, and reduce its cost from about 1.3 million riyals to 250,000 riyals, a drop of nearly 80%, strengthening the potential to make these advanced therapies available to patients and reducing reliance on manufacturing abroad.
The development of local manufacturing capabilities comes as an extension of the Specialist Hospital's efforts to localize advanced therapies, in line with the targets of the National Biotechnology Strategy, which aims to cement Saudi Arabia's position as a global hub for life sciences innovation and the development of advanced biotechnology industries.